Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Moderna (DE:0QF)
XETRA:0QF
Holding DE:0QF?
Track your performance easily
0QF Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€56.89 - €156.54
Previous Close€57.53
Volume280.00
Average Volume (3M)8.75K
Market Cap
€21.96B
Enterprise Value€15.44B
Total Cash (Recent Filing)$8.49B
Total Debt (Recent Filing)$1.24B
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Oct 31, 2024EPS Estimate
-€1.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding384,396,030
10 Day Avg. Volume18,914
30 Day Avg. Volume8,753
Standard Deviation0.20
R-Squared0.00752
Alpha0.00620
Financial Highlights & Ratios
Price to Book (P/B)1.89
Price to Sales (P/S)4.93
Price to Cash Flow (P/CF)-4.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.06
Enterprise Value/Gross Profit7.49
Enterprise Value/Ebitda-4.07
Forecast
1Y Price Target
€93.84Price Target Upside64.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering19
Moderna News
PremiumMarket News
SPY ETF Update, 9/26/2024 
PremiumMarket News
QQQ ETF Update, 9/25/2024 
PremiumMarket News
VOO ETF Update, 9/24/2024 
PremiumMarket News
QQQ ETF Update, 9/23/2024 
PremiumMarket News
SPY ETF Update, 9/20/2024 
PremiumMarket News
VOO ETF Update, 9/19/2024 
PremiumMarket News
VOO ETF Update, 9/16/2024 Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentModerna's individualized neoantigen therapy is currently in phase 3, showing great potential despite uncertainty in its respiratory vaccine franchise.
New Product LaunchesFaster market penetration for new drug launches such as CIC, RSV, and CMV could provide upside to company guidance on sales and operating margins.
Regulatory FilingRegulatory filing for mRNA-1083 gives MRNA first mover advantage in the COVID/flu combo vaccine market.
Bears Say
Financial GuidanceRevised FY25 revenue guidance is now $2.5B to $3.5B, capturing an estimate of $2.57B.
R&D And ProfitabilityFuture OpEx cuts are necessary to get the company back to sustainability.
Regulatory ChallengesInitial FDA feedback has not been supportive of accelerated approval for mRNA-4157 (partnered with MRK) in adjuvant melanoma, and the company terminated several pipeline programs.
---
Options Prices
Currently, No data available
---
Ownership Overview
14.68% Insiders
22.90% Mutual Funds
45.83% Other Institutional Investors
16.58% Public Companies and
Individual Investors
0QF FAQ
What was Moderna’s price range in the past 12 months?
Moderna lowest stock price was €56.89 and its highest was €156.54 in the past 12 months.
What is Moderna’s market cap?
Currently, no data Available
When is Moderna’s upcoming earnings report date?
Moderna’s upcoming earnings report date is Oct 31, 2024 which is in 34 days.
How were Moderna’s earnings last quarter?
Moderna released its earnings results on Aug 01, 2024. The company reported -€2.976 earnings per share for the quarter, beating the consensus estimate of -€2.992 by €0.016.
Is Moderna overvalued?
According to Wall Street analysts Moderna’s price is currently Undervalued.
Does Moderna pay dividends?
Moderna does not currently pay dividends.
What is Moderna’s EPS estimate?
Moderna’s EPS estimate is -€1.65.
How many shares outstanding does Moderna have?
Moderna has 384,396,030 shares outstanding.
What happened to Moderna’s price movement after its last earnings report?
Moderna reported an EPS of -€2.976 in its last earnings report, beating expectations of -€2.992. Following the earnings report the stock price went down -20.611%.
Which hedge fund is a major shareholder of Moderna?
Among the largest hedge funds holding Moderna’s share is Theleme Partners Llp. It holds Moderna’s shares valued at 858M.
---
Moderna Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€93.84 (64.25% Upside)
€93.84 (64.25% Upside)
Blogger Sentiment
Neutral
DE:0QF Sentiment 59%
Sector Average 71%
Sector Average 71%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.17%
12-Months-Change
Fundamentals
Return on Equity
-40.94%
Trailing 12-Months
Asset Growth
-28.35%
Trailing 12-Months
Company Description
Moderna
Incorporated in 2010, Massachusetts-based Moderna, Inc. is a clinical stage biotechnology company which develops therapeutics and vaccines based on messenger ribonucleic acid (mRNA) for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.
---
0QF Company Deck
---
0QF Earnings Call
Q2 2024
0:00 / 0:00
---
0QF Revenue Breakdown
52.54% Rest of World
27.67% U.S.
19.79% Europe
---
0QF Stock 12 Month Forecast
Average Price Target
€93.84
▲(64.25% Upside)
Technical Analysis
Best Analysts Covering 0QF
1 Year
1 Year Success Rate
30/37 ratings generated profit
1 Year Average Return
-12.74%
reiterated a sell rating 14 days ago
Copying Mani Foroohar's trades and holding each position for 1 Year would result in 81.08% of your transactions generating a profit, with an average return of -12.74% per trade.
---